HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Fabian Ziller Selected Research

Nivolumab

5/2023Real-world outcomes using PD-1 antibodies and BRAF + MEK inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and Switzerland.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Fabian Ziller Research Topics

Disease

4Melanoma (Melanoma, Malignant)
05/2023 - 05/2021
4Skin Neoplasms (Skin Cancer)
05/2023 - 05/2021
3Neoplasms (Cancer)
01/2023 - 05/2021
3Neoplasm Metastasis (Metastasis)
01/2023 - 07/2021
2Uveal melanoma
01/2022 - 07/2021
1Brain Neoplasms (Brain Tumor)
01/2023
1Disease Progression
05/2021

Drug/Important Bio-Agent (IBA)

3Immune Checkpoint InhibitorsIBA
01/2023 - 07/2021
2Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
01/2023 - 05/2021
1pembrolizumabIBA
05/2023
1NivolumabIBA
05/2023
1AntibodiesIBA
05/2023
1cyclopropapyrroloindoleIBA
01/2023
1L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA
01/2023

Therapy/Procedure

4Therapeutics
05/2023 - 05/2021
1Withholding Treatment
05/2021